Heparin-binding protein as a biomarker of severe sepsis in the pediatric intensive care unit : A multicenter, prospective study
Copyright © 2022 Elsevier B.V. All rights reserved..
OBJECTIVES: The aim of this study is to assess Heparin-binding protein (HBP) as a diagnostic and prognostic biomarker of severe sepsis in the pediatric intensive care unit (PICU).
METHODS: A multicenter, prospective study was conducted among children with sepsis in nine PICUs in China from October 2019 to June 2021. Plasma levels of HBP, procalcitonin (PCT), C-reactive protein (CRP), lactate, and white blood cell (WBC) count were determined at enrollment and 72 h after enrollment.
RESULTS: Of 355 included patients, 132 patients were diagnosed with non-severe sepsis (referred to as sepsis), 223 patients had severe sepsis. Patients with severe sepsis had significantly elevated levels of HBP compared with sepsis (median 170.5 vs. 74.1 ng/mL, P < 0.001). Adding HBP to a diagnostic model with PCT and lactate could significantly improve the diagnostic capability for severe sepsis. The plasma levels of HBP correlated positively with the number of dysfunctional organs. After adjusting for confounding factors, the declined levels of HBP at 72 h had a significant association with decreased in-hospital mortality (adjusted odds ratio (aOR) 0.242, P < 0.001). The levels of HBP showed weak positive correlations with PCT, CRP, WBC, and no correlation to lactate.
CONCLUSIONS: HBP at enrollment can be an independent indicator for severe sepsis and the dynamic changes at 72 h can be a predictor for in-hospital mortality in PICU.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:539 |
|---|---|
| Enthalten in: |
Clinica chimica acta; international journal of clinical chemistry - 539(2023) vom: 15. Jan., Seite 26-33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Pengcheng [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.02.2023 Date Revised 02.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cca.2022.11.028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349726876 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349726876 | ||
| 003 | DE-627 | ||
| 005 | 20231226043319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cca.2022.11.028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349726876 | ||
| 035 | |a (NLM)36460135 | ||
| 035 | |a (PII)S0009-8981(22)01395-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Pengcheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heparin-binding protein as a biomarker of severe sepsis in the pediatric intensive care unit |b A multicenter, prospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2023 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVES: The aim of this study is to assess Heparin-binding protein (HBP) as a diagnostic and prognostic biomarker of severe sepsis in the pediatric intensive care unit (PICU) | ||
| 520 | |a METHODS: A multicenter, prospective study was conducted among children with sepsis in nine PICUs in China from October 2019 to June 2021. Plasma levels of HBP, procalcitonin (PCT), C-reactive protein (CRP), lactate, and white blood cell (WBC) count were determined at enrollment and 72 h after enrollment | ||
| 520 | |a RESULTS: Of 355 included patients, 132 patients were diagnosed with non-severe sepsis (referred to as sepsis), 223 patients had severe sepsis. Patients with severe sepsis had significantly elevated levels of HBP compared with sepsis (median 170.5 vs. 74.1 ng/mL, P < 0.001). Adding HBP to a diagnostic model with PCT and lactate could significantly improve the diagnostic capability for severe sepsis. The plasma levels of HBP correlated positively with the number of dysfunctional organs. After adjusting for confounding factors, the declined levels of HBP at 72 h had a significant association with decreased in-hospital mortality (adjusted odds ratio (aOR) 0.242, P < 0.001). The levels of HBP showed weak positive correlations with PCT, CRP, WBC, and no correlation to lactate | ||
| 520 | |a CONCLUSIONS: HBP at enrollment can be an independent indicator for severe sepsis and the dynamic changes at 72 h can be a predictor for in-hospital mortality in PICU | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Children | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Heparin-binding protein (HBP) | |
| 650 | 4 | |a Pediatric intensive care unit (PICU) | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Severe sepsis | |
| 650 | 7 | |a AZU1 protein, human |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Procalcitonin |2 NLM | |
| 650 | 7 | |a Lactic Acid |2 NLM | |
| 650 | 7 | |a 33X04XA5AT |2 NLM | |
| 700 | 1 | |a Chen, Dapeng |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Jintu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jiancheng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Caizhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Cai |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Haiming |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Gangfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhenwen |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Guangfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Lijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Shuzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Liya |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Shiqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinica chimica acta; international journal of clinical chemistry |d 1956 |g 539(2023) vom: 15. Jan., Seite 26-33 |w (DE-627)NLM000002054 |x 1873-3492 |7 nnns |
| 773 | 1 | 8 | |g volume:539 |g year:2023 |g day:15 |g month:01 |g pages:26-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cca.2022.11.028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 539 |j 2023 |b 15 |c 01 |h 26-33 | ||